|Other Names||Glypican-3, GTR2-2, Intestinal protein OCI-5, MXR7, Secreted glypican-3, GPC3, OCI5|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6337a was selected from the N-term region of human GPC3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Cell surface proteoglycan that bears heparan sulfate. Inhibits the dipeptidyl peptidase activity of DPP4. May be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs. May play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. May regulate growth and tumor predisposition.|
|Cellular Location||Cell membrane; Lipid-anchor, GPI-anchor; Extracellular side|
|Tissue Location||Highly expressed in lung, liver and kidney.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
GPC3 is a cell surface proteoglycan that bears heparan sulfate. This protein may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. Members of the glypican-related integral membrane proteoglycan family contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol (GPI) linkage. These proteins may play a role in the control of cell division, growth regulation, and tumor predisposition. Deletion mutations in GPC3 are the cause of Simpson-Golabi-Behmel syndrome (SGBS), also known as Simpson dysmorphia syndrome (SDYS). SGBS is a condition characterized by pre- and postnatal overgrowth (gigantism) with visceral and skeletal anomalies.
Nakatsura, T., et al., Clin. Cancer Res. 10(19):6612-6621 (2004).Boily, G., et al., Br. J. Cancer 90(8):1606-1611 (2004).Wichert, A., et al., Oncogene 23(4):945-955 (2004).Midorikawa, Y., et al., Int. J. Cancer 103(4):455-465 (2003).Sung, Y.K., et al., Cancer Sci. 94(3):259-262 (2003).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.